Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery

Chauhan, Iti; Yasir, Mohd; Verma, Madhu; Singh, Alok Pratap

doi:10.34172/apb.2020.021

Cited by 269 publications

(183 citation statements)

References 80 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…This lipid is non-toxic, non-irritating, widely used in pharmaceutical, cosmetic, and food industries [34]. The surfactant (its type and concentration) affects the NLC quality, being important in obtaining stable systems, in drug solubility and in the release or penetration process [16]. The selection of surfactant in this study was based on ETD solubility tests.…”

Section: Discussionmentioning

confidence: 99%

“…NLC are regarded as non-toxic and biocompatible with skin and mucosal tissues, demonstrating occlusion and skin-hydrating effect. After application to the skin, NLC form a mono-layered lipid film on the skin, show an occlusion effect, reduce corneocyte packing, and can improve drug penetration to deeper layers [ 13 , 14 , 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanostructured Lipid Carriers Engineered as Topical Delivery of Etodolac: Optimization and Cytotoxicity Studies

et al. 2021

View full text Add to dashboard Cite

Etodolac (ETD), a nonsteroidal anti-inflammatory drug, exhibits antinflammatory, analgesic, and antipyretic activity. The main type of ETD administration is oral route, which is associated with significant systemic side effects. Nanostructured lipid carriers (NLC), a modern lipid formulation, are non-toxic, biocompatible, can improve the solubility and stability of drugs. Nanostructured lipid carriers (NLC) containing etodolac were prepared by a melt-emulsification and ultrasonication technique. Full factorial design (FFD) was applied to optimize the composition of NLC and their properties such as zeta potential, polidyspersity index, and entrapment efficiency. Formulations consisting of Capryol 90, glicerol monostearate, and Tween 20 displayed particle size below 300 nm, encapsulated drug with efficiency of approximately 87% and prolonged drug release up to 24 h. Stable formulations displayed moderately negative surface charge suggesting their limited ability to interact with skin surface but simultaneously presenting their lower risk to cause cell-membrane disruption. In fact, cytotoxicity assessment using human dermal fibroblasts and human epidermal keratinocytes revealed that etodolac-loaded NLC had no important impact on skin cells viability evaluated in vitro, which might evidence that NLC formulations are safe for dermal delivery. The studies developed were relatively fast and simple, requiring no specialized equipment method to prepare NLC as ETD carriers ensuring better solubility and prolonged drug release.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nanostructured Lipid Carriers Engineered as Topical Delivery of Etodolac: Optimization and Cytotoxicity Studies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These were due to the addition of liquid lipids into the SA lead to order crystal structure became disordered. Disorders of the crystal structure leave enough space for the incorporation of drug molecules [27]. The EE and DL of co-Q10 NLC (F8) were the highest.…”

Section: Fourier Transform Infrared (Ft-ir)mentioning

confidence: 99%

“…The CI was calculated by comparing the enthalpy of co-Q10 NLC with the enthalpy of SA (equation 1). Lipid crystallinity affects EE and DL [7,27]. The CI of co-Q10 NLC (F6), (F7), and (F8) are presented in table 6.…”

Section: Morphology Of the Co-q10 Nlcsmentioning

confidence: 99%

EXPERIMENTAL DEVELOPMENT AND MOLECULAR DOCKING: NANOSTRUCTURED LIPID CARRIERS (NLCs) OF COENZYME Q10 USING STEARIC ACID AND DIFFERENT LIQUID LIPIDS AS LIPID MATRIX

Aryani¹,

Siswandono²,

Soeratri³

et al. 2021

Int J App Pharm

View full text Add to dashboard Cite

Objective: To develop coenzyme Q10 (co-Q10) nanostructured lipid carriers (NLCs) using stearic acid (SA) and various liquid lipids with different lipophilicity as well as highlights the use of in silico studies for predicting and elucidating the interaction of drug-lipid used as carries in NLCs, at the molecular level. Methods: The co-Q10 NLCs were prepared using SA as solid lipid and oleic acid (OA), isopropyl myristate (IPM), as well as isopropyl palmitate (IPP) as liquid lipids by the high shear homogenization method. Firstly, the formulas were optimized by the appropriate required HLB (rHLB). The optimized NLCs were characterized in the particle size, distribution of particle size, zeta potential, crystallinity behavior, Fourier transform infrared (FT-IR) spectra, morphology, entrapment efficiency (EE), drug loading (DL), and pH value. The interaction of drug-lipids in silico was studied using the AutoDock Vina program. Results: The co-Q10 NLCs using SA and the various liquid lipid possessed the mean particle size, polydispersity index (PDI), zeta potential, EE, DL, and pH values were 180 to 350 nm,<0.5,<-30 mV, 83 to 88%, 10 to 11%, and 5.0 to 5.6, respectively. The EE and DL of co-Q10 NLCs increased with decreasing in binding energy (∆G) in silico. Conclusion: The co-Q10 NLCs using SA as solid lipid and OA, IPM, as well as IPP as liquid lipids were developed successfully. Furthermore, in silico study by molecular docking is a potential approach in predicting and elucidating the interaction of drug-lipid in the development of NLCs formulation.

show abstract

“…NLCs are formed by utilizing solid lipid and liquid lipid which ultimately forms the less perfect crystalline structure with many imperfections providing more space for drug accommodation ( 61 , 62 ). Many studies came to conclusion that small-size lipid carrier ensures close contact to the stratum corneum and can improve penetration of therapeutic moiety into the skin ( 63 , 64 ). The epidermal targeting may be exploited using NLCs and SLNs as well as reduction of side effects can be achieved.…”

Section: Nanomedicines For Atopic Dermatitis—current Scenariomentioning

confidence: 99%

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

et al. 2021

View full text Add to dashboard Cite

Globally, the prevalence of Atopic dermatitis (AD) is significantly increasing and affecting around 20% of population including children. Complex interactions amongst abnormality in epidermal barrier function, environment, infectious agents and immunological defects are considered as key factors in the pathogenesis of AD. Although the role of oxidative stress has been studied in some skin diseases, investigation of the same in AD is intermittent. Calcineurin inhibitors and/or topical corticosteroids are currently available; however, it causes atrophy of the skin, burning sensation, and systemic side effects which leads to poor patient compliance. These limitations provoke the strong need to develop an innovative approach in managing AD. Nanomaterials for effective drug delivery to skin conditions such as AD have attracted a lot of attention owing to its ability to encapsulate, protect, and release the cargo at the diseased skin site. However, there are lots of unmet challenges especially in terms of development of non-toxic formulations and clinical translation of established nanomedicines in the form of accessible products. Numerous formulations have emerged as carrier for poorly soluble and permeable drugs, viz., lipidic, polymeric, metal, silica, liposomes, hydrocarbon gels and this field is evolving. This review is intended to provide an insight incidences associated with pathophysiology of AD and challenges with existing treatments of AD. Focus is kept on reviewing current development and emerging nanomedicines for effective treatment of AD. The review also inculcates merits of several nanomedicines in overcoming challenges of existing products and its future implications.

show abstract

Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery

Cited by 269 publications

References 80 publications

Nanostructured Lipid Carriers Engineered as Topical Delivery of Etodolac: Optimization and Cytotoxicity Studies

Nanostructured Lipid Carriers Engineered as Topical Delivery of Etodolac: Optimization and Cytotoxicity Studies

EXPERIMENTAL DEVELOPMENT AND MOLECULAR DOCKING: NANOSTRUCTURED LIPID CARRIERS (NLCs) OF COENZYME Q10 USING STEARIC ACID AND DIFFERENT LIQUID LIPIDS AS LIPID MATRIX

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

Contact Info

Product

Resources

About